Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 130
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Pediatr ; 274: 114176, 2024 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-38945446

RESUMEN

OBJECTIVE: The objective of this study was to describe reported adverse events (AEs) associated with elexacaftor/tezacaftor/ivacaftor (ETI) in a pediatric sample with cystic fibrosis (CF) aged 6-18 years, with at least one F508del variant, followed at multiple Italian CF centers. STUDY DESIGN: This was a retrospective, multicenter, observational study. All children receiving ETI therapy from October 2019 to December 2023 were included. We assessed the prevalence and type of any reported potential drug-related AEs, regardless of discontinuation necessity. Persistent AEs were defined as those continuing at the end of the observation period. RESULTS: Among 608 patients on ETI, 109 (17.9%) reported at least 1 AE. The majority (n = 85, 77.9%) were temporary, with a median duration of 11 days (range 1-441 days). Only 7 (1.1%) patients permanently discontinued treatment, suggesting good overall safety of ETI. The most common AEs leading to discontinuation were transaminase elevations (temporary 14.1%, persistent 25.9%) and urticaria (temporary 41.2%, persistent 7.4%). Creatinine phosphokinase elevation was uncommon. No significant differences in AEs were observed based on sex, age groups (6-11 vs 12-18 years), or genotype. Pre-existing CF-related liver disease was associated with an increased risk of transaminase elevations. We identified significant variability in the percentage of reported AEs (ANOVA P value .026). CONCLUSIONS: This real-world study highlights significant variability in reported AEs. Our findings suggest that ETI is a safe and well-tolerated therapy in children and adolescents with CF. However, further long-term safety and effectiveness investigations are warranted.


Asunto(s)
Aminofenoles , Benzodioxoles , Regulador de Conductancia de Transmembrana de Fibrosis Quística , Fibrosis Quística , Combinación de Medicamentos , Indoles , Quinolonas , Humanos , Adolescente , Niño , Masculino , Femenino , Fibrosis Quística/tratamiento farmacológico , Fibrosis Quística/genética , Estudios Retrospectivos , Benzodioxoles/efectos adversos , Benzodioxoles/uso terapéutico , Aminofenoles/efectos adversos , Aminofenoles/uso terapéutico , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Indoles/efectos adversos , Quinolonas/efectos adversos , Quinolonas/uso terapéutico , Piridinas/efectos adversos , Pirazoles/efectos adversos , Pirroles/efectos adversos , Alelos , Italia , Pirrolidinas
2.
Paediatr Respir Rev ; 51: 46-55, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38309973

RESUMEN

OBJECTIVES: Aim of this study was to identify risk factors for a progression to cystic fibrosis (CF) in individuals detected as CF Screening Positive, Inconclusive Diagnosis (CFSPID). METHODS: This is a systematic review through literature databases (2015-2023). Blood immunoreactive trypsinogen (b-IRT) values, CFTR genotype, sweat chloride (SC) values, isolation of Pseudomonas aeruginosa (Pa) from respiratory samples, Lung Clearance Index (LCI) values in CFSPIDs who converted to CF (CFSPID > CF) and age at CF transition were assessed. RESULTS: Percentage of CFSPID > CF varies from 5.3 % to 44 %. Presence of one CF-causing CFTR variant in trans with a variant with variable clinical consequences (VVCC), an initial SC ≥ 40 mmol/L, an increase of SC > 2.5 mmol/L/year and recurrent isolation of pseudomonas aeruginosa (Pa) from airway samples could allow identification of subjects at risk of progression to CF. CONCLUSIONS: CFSPIDs with CF causing variant/VVCC genotype and first SC in the higher borderline range may require more frequent and prolonged clinical follow-up.


Asunto(s)
Regulador de Conductancia de Transmembrana de Fibrosis Quística , Fibrosis Quística , Progresión de la Enfermedad , Infecciones por Pseudomonas , Pseudomonas aeruginosa , Humanos , Cloruros/análisis , Fibrosis Quística/diagnóstico , Fibrosis Quística/genética , Fibrosis Quística/microbiología , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Genotipo , Pseudomonas aeruginosa/aislamiento & purificación , Infecciones por Pseudomonas/diagnóstico , Infecciones por Pseudomonas/microbiología , Factores de Riesgo , Sudor/química
3.
Pediatr Allergy Immunol ; 33 Suppl 27: 15-17, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-35080292

RESUMEN

Recently, type 2 inflammation has been recognized as one of the most critical factors participating in the pathogenesis of cystic fibrosis (CF). On the one hand, type 2 inflammation restores tissue homeostasis and contributes to the resolution of inflammation following an injury. On the other hand, type 2 response-activated immune cells may become dysregulated or chronically activated, causing tissue fibrosis. Among the type 2 cytokine-driven inflammatory pathways, the transforming growth factor ß (TGFß), interleukin (IL)-17, IL-33, and IL-13 have been identified as essential mediators in patients suffering from CF. Given their critical role, we firmly believe that an adequate comprehension of the type 2-mediated pathways can identify attractive targets to decrease pharmacologically the inflammation and fibrosis occurring in the pulmonary tissue of patients suffering from CF.


Asunto(s)
Fibrosis Quística , Citocinas/metabolismo , Humanos , Inflamación/metabolismo , Mediadores de Inflamación/metabolismo , Pulmón/metabolismo
4.
Pediatr Allergy Immunol ; 33 Suppl 27: 99-101, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-35080301

RESUMEN

More than a year and a half after the beginning of the coronavirus disease 2019 (COVID-19) pandemic, symptoms, such as loss of smell and taste (anosmia and ageusia, respectively), remain difficult to characterize and quantify, especially in children, since no validated tests to assess these disorders are available. However, these symptoms can also be seen in children, although less frequently than observed in the adult population. In this article, we present the results of a national survey that collected the responses of 267 Italian pediatricians on the presence of anosmia and ageusia in children affected by COVID-19. These data were then compared with existing literature.


Asunto(s)
Ageusia , COVID-19 , Adulto , Anosmia , Niño , Humanos , Pandemias , SARS-CoV-2
5.
Molecules ; 27(16)2022 Aug 21.
Artículo en Inglés | MEDLINE | ID: mdl-36014562

RESUMEN

There is substantial evidence in the literature that patients with cystic fibrosis (CF) have higher oxidative stress than patients with other diseases or healthy subjects. This results in an increase in reactive oxygen species (ROS) and in a deficit of antioxidant molecules and plays a fundamental role in the progression of chronic lung damage. Although it is known that recurrent infection-inflammation cycles in CF patients generate a highly oxidative environment, numerous clinical and preclinical studies suggest that the airways of a patient with CF present an inherently abnormal proinflammatory milieu due to elevated oxidative stress and abnormal lipid metabolism even before they become infected. This could be directly related to cystic fibrosis transmembrane conductance regulator (CFTR) deficiency, which appears to produce a redox imbalance in epithelial cells and extracellular fluids. This review aims to summarize the main mechanism by which CFTR deficiency is intrinsically responsible for the proinflammatory environment that characterizes the lung of a patient with CF.


Asunto(s)
Fibrosis Quística , Fibrosis Quística/genética , Fibrosis Quística/metabolismo , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Humanos , Pulmón/metabolismo , Estrés Oxidativo , Especies Reactivas de Oxígeno/metabolismo
6.
Int J Mol Sci ; 22(5)2021 Feb 28.
Artículo en Inglés | MEDLINE | ID: mdl-33671104

RESUMEN

In recent years, there has been a growth in scientific interest in nutraceuticals, which are those nutrients in foods that have beneficial effects on health. Nutraceuticals can be extracted, used for food supplements, or added to foods. There has long been interest in the antiviral properties of nutraceuticals, which are especially topical in the context of the ongoing COVID-19 pandemic. Therefore, the purpose of this review is to evaluate the main nutraceuticals to which antiviral roles have been attributed (either by direct action on viruses or by modulating the immune system), with a focus on the pediatric population. Furthermore, the possible applications of these substances against SARS-CoV-2 will be considered.


Asunto(s)
Antivirales/uso terapéutico , COVID-19/prevención & control , Suplementos Dietéticos , Virosis/prevención & control , Niño , Humanos , Probióticos/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2/efectos de los fármacos
7.
Pediatr Allergy Immunol ; 31 Suppl 24: 34-36, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32017222

RESUMEN

Antihistamines are currently one of the most commonly administered drugs in children. They are used to treat symptoms that depend on histamine release, namely allergic diseases, such as rhinitis, asthma, urticaria, and anaphylaxis. It is possible to distinguish first- and second-generation antihistamines. Pharmacological effects and therapeutic indications are similar, but second-generation antihistamines have fewer adverse effects because they are more selective for peripheral H1 receptors. Although they have been on the market for several years, there are still many adverse effects linked to the antihistamine safety profile, especially in the first years of life. Thus, many antihistamines are prescribed off-label, especially in children younger than 2 years of age, which is the age-group where most of the data on drug safety are lacking and many antihistamines are not recommended. This article aims to provide a practical update on the use of antihistamines in children.


Asunto(s)
Antagonistas de los Receptores Histamínicos/uso terapéutico , Histamina/metabolismo , Hipersensibilidad/tratamiento farmacológico , Niño , Preescolar , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Humanos , Lactante , Pediatras , Guías de Práctica Clínica como Asunto , Receptores Histamínicos H1/metabolismo
8.
Pediatr Allergy Immunol ; 31 Suppl 26: 20-22, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33236425

RESUMEN

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease caused by Aspergillus induced hypersensitivity that occurs in immunocompetent but susceptible patients with asthma and/or cystic fibrosis (CF). In children, ABPA remains mostly undiagnosed resulting in one of the most common causes of poorly controlled asthma and highly significant morbidity in children with CF. Currently, no specific diagnostic criteria of ABPA for children are available. Corticosteroids and itraconazole are the mainstays of therapy although there is a lack of randomized clinical trials regarding their usefulness for ABPA in children. Several monoclonal antibodies, such as omalizumab and mepolizumab, may be potential therapies for refractory ABPA in pediatric patients; however, further data are required to clarify the optimal dose and duration of therapy as a routine treatment approach.


Asunto(s)
Aspergilosis Broncopulmonar Alérgica , Fibrosis Quística , Antifúngicos/uso terapéutico , Aspergilosis Broncopulmonar Alérgica/diagnóstico , Aspergilosis Broncopulmonar Alérgica/tratamiento farmacológico , Niño , Fibrosis Quística/tratamiento farmacológico , Humanos , Itraconazol , Omalizumab/uso terapéutico
9.
Pediatr Allergy Immunol ; 31 Suppl 26: 85-88, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33236430

RESUMEN

The clinical spectrum of SARS-CoV-2 infection is mixed. It ranges from asymptomatic cases, medium-intensity forms with mild to moderate symptoms, to severe ones with bilateral lung involvement and respiratory distress, which can require transfer to ICUs and intubation. In most cases, the clinical picture is characterized by a persistent fever, cough, dyspnoea, expectoration, myalgias, arthralgias, headache, gastrointestinal symptoms, nasal congestion, and pharyngodynia. The spread of COVID-19 in Europe has highlighted an atypical presentation of disease involving upper airways and, above all, dysfunction of olfactory and gustatory senses. There is ample evidence that COVID-19 is significantly less severe in children than in adults. However, due to difficulties in assessing the disorder in children, especially among very young patients, the olfaction and gustatory dysfunctions remain open issues. This article sheds light on the upper airway involvement in pediatric COVID-19 subjects.


Asunto(s)
Ageusia/etiología , Anosmia/etiología , COVID-19/complicaciones , SARS-CoV-2 , Ageusia/diagnóstico , Anosmia/diagnóstico , Niño , Humanos
10.
Clin Mol Allergy ; 18: 2, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32127782

RESUMEN

Cetirizine is a second-generation antihistamine, derived from the metabolism of hydroxyzine, highly specific for the H1 receptors, and with marked antiallergic properties. Although its history began more than 30 years ago, it remains one of the most used drugs in children with a leading role in the medical care of children with allergic diseases. Cetirizine use is licensed for paediatric patients for the treatment of allergic rhinitis, and chronic spontaneous urticaria, in Europe in children older than 2 years old and in the USA in children older than 6 months old. This review provides a practical update on the use of cetirizine in children and adolescents.

11.
Minerva Pediatr ; 72(5): 358-363, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32731733

RESUMEN

The rising incidence of allergic disease requires more specific, effective and safe therapeutic strategies. In this regard, several kinds of biologically active substances, commonly known as immunostimulants, have been introduced for the prevention and treatment of allergic diseases in pediatric population. Among the heterogeneous group of biologically active molecules to date available, pidotimod (Axil, Valeas S.p.A, Milan) is proved to be able to ameliorate both innate and adaptive immunity and enhances the immune system properties often impaired in patients with allergic disorders.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Hipersensibilidad/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Ácido Pirrolidona Carboxílico/análogos & derivados , Tiazolidinas/uso terapéutico , Inmunidad Adaptativa , Adyuvantes Inmunológicos/farmacología , Adolescente , Asma/tratamiento farmacológico , Asma/inmunología , Niño , Preescolar , Urticaria Crónica/tratamiento farmacológico , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/inmunología , Desensibilización Inmunológica , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Humanos , Hipersensibilidad/inmunología , Inmunidad Innata/efectos de los fármacos , Factores Inmunológicos/farmacología , Ácido Pirrolidona Carboxílico/farmacología , Ácido Pirrolidona Carboxílico/uso terapéutico , Rinitis Alérgica/tratamiento farmacológico , Rinitis Alérgica/inmunología , Tiazolidinas/farmacología
13.
Pediatr Blood Cancer ; 66(5): e27600, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30604464

RESUMEN

BACKGROUND: Following diagnosis, children with cancer suddenly find themselves in an unknown world where unfamiliar adults make all the important decisions. Children typically experience increasing levels of anxiety with repeated invasive procedures and do not adapt to the discomfort. The aim of the present study is to explore the possibility of asking children directly about their medical support preferences during invasive procedures. PROCEDURE: Each patient was offered a choice of medical support on the day of the procedure, specifically general anesthesia (GA), conscious sedation (CS), or nothing. An ad hoc assessment tool was prepared in order to measure child discomfort before, during, and after each procedure, and caregiver adequacy was measured. Both instruments were completed at each procedure by the attending psychologist. RESULTS: We monitored 247 consecutive invasive procedures in 85 children and found that children in the 4 to 7 year age group showed significantly higher distress levels. GA was chosen 66 times (26.7%), CS was chosen 97 times (39.3%), and nothing was chosen 5 times and exclusively by adolescents. The child did not choose in 79 procedures (32%). The selection of medical support differed between age groups and distress level was reduced at succeeding procedures. CONCLUSIONS: Offering children the choice of medical support during invasive procedures allows for tailored support based on individual needs and is an effective modality to return active control to young patients, limiting the emotional trauma of cancer and treatment.


Asunto(s)
Anestesia General/métodos , Cuidadores/psicología , Niño Hospitalizado/psicología , Sedación Consciente/métodos , Toma de Decisiones , Neoplasias/terapia , Dolor/prevención & control , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Masculino
15.
Radiol Med ; 124(2): 136-144, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30368721

RESUMEN

A systematic literature was performed to assess the benefit in terms of effectiveness and feasibility of hypofractionated radiotherapy (HypoRT), with or without chemotherapy (CT), in the treatment of locally advanced non-small cell lung cancer (NSCLC). We have identified all studies, published from 2007 onwards, on patients with locally advanced NSCLC treated with HypoRT with radical intent, with a minimal dose per fraction of 2.4 Gy, with or without concurrent chemotherapy. Twenty-nine studies were identified, for a total of 2614 patients. Patients were divided in the concurrent chemo-radiation therapy group (CT-RT) and radiotherapy alone (RT). In RT group, the delivered dose ranged from 45 to 85.5 Gy, with a dose/fraction from 2.4 to 4 Gy. Actuarial 2-year PFS ranged from 13 to 57.8%, and 1, 2- and 3-year overall survival (OS) ranged from 51.3 to 95%, from 22 to 68.7%, and from 7 to 32%, respectively. Acute Grade ≥ 3 esophagitis occurred in 0-15%, while late esophageal toxicity was 0-16%. Acute pneumonitis occured in 0-44%, whereas late pneumonitis occured in 0-47%, most commonly grade ≤ G3. In CT-RT group, the delivered dose ranged from 52.5 to 75 Gy, with a dose/fraction ranging from 2.4 to 3.5 Gy. Actuarial 2-year PFS ranged from 19 to 57.8%, and OS at 1, 2 and 3 years ranged from 28 to 95%, 38.6 to 68.7%, and 31 to 44%, respectively. Acute Grade 2 and 3 esophagitis occurred in 3-41.7%, while late esophageal toxicity occurred in 0-8.3%. Acute pneumonitis ranged from 0 to 23%, whereas late pneumonitis occured 0-47%. HypoRT seems to be safe in patients with locally advanced NSCLC. The encouraging survival results of several studies analyzed suggest that hypofractionated radiation schemes should be further investigated in the future.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Fraccionamiento de la Dosis de Radiación , Neoplasias Pulmonares/radioterapia , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Quimioradioterapia/métodos , Humanos , Neoplasias Pulmonares/tratamiento farmacológico
16.
Radiol Med ; 124(9): 854-859, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30963379

RESUMEN

PURPOSE: To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, namely image-guided intensity-modulated RT (IG-IMRT). METHODS AND MATERIALS: Fifty-four patients were analyzed. Minimum radiation dose was 50 Gy (2 Gy/fr). Planning target volume encompassed the entire hemithorax, including the ipsilateral mediastinum if interested by disease, the pericardium and diaphragm, and any drain sites. The study endpoints included loco-regional control (LRC), distant metastases free survival (DMFS), and overall survival (OS), as well as radiation-related toxicity. RESULTS: Major patients and treatment characteristics were the following: median age 62 years, epithelioid histology in 51 (94%) cases, locally advanced disease in 41 (90%) cases, and metastatic mediastinal lymph nodes in 27 patients (50%). Only 7 patients (13%) had gross residual disease after surgery. Chemotherapy was administered in 38 patients (70%). Median follow-up was 16 months (range 0-73 months). Median and 2-year OS were 21 months and was 43.8%, respectively. The predominant pattern of failure was distant: 34 patients (62.9%) developed some component of distant failure, and only 5 patients (9.2%) developed an isolated loco-regional recurrence. The estimates of LRC and DMFS at 2 years were 63.4% and 43.4%, respectively. Three fatal pneumonitis were documented. Other major toxicities included: Grade 2 and 3 pneumonitis in 1 and 2 cases, respectively, 1 case of bronchial fistula, pleural empyema, and Grade 3 esophagitis, respectively. CONCLUSIONS: Although executed in the era of high-technology radiotherapy (IG-IMRT), EPP should not be routinely performed.


Asunto(s)
Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/cirugía , Mesotelioma/radioterapia , Mesotelioma/cirugía , Neoplasias Pleurales/radioterapia , Neoplasias Pleurales/cirugía , Neumonectomía/métodos , Radioterapia Guiada por Imagen , Radioterapia de Intensidad Modulada/métodos , Adulto , Anciano , Femenino , Humanos , Masculino , Mesotelioma Maligno , Persona de Mediana Edad , Pleura , Radioterapia Adyuvante/métodos , Estudios Retrospectivos , Resultado del Tratamiento
17.
Minerva Pediatr ; 71(6): 515-523, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31129955

RESUMEN

INTRODUCTION: Gastro-esophageal reflux disease (GERD) indicates a gastroesophageal reflux that causes symptoms such as pain, and needs medical therapy, and may result in complications such as erosive esophagitis, aspiration pneumonia. Here, we review if it exists a real link between clinical presentation of some respiratory diseases such as asthma, chronic cough, cystic fibrosis and laryngopharyngitis and GERD. EVIDENCE ACQUISITION: This review was conducted employing 2 databases: PubMed and Science Direct. EVIDENCE SYNTHESIS: Asthma may lead to reflux, and reflux could exacerbate asthma or cause asthma-like symptoms. Prevalence of GERD in children with asthma ranged from as low 32% to as high 80%. There are several studies where the use of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists lead to inconclusive results. The relation of chronic unexplained cough to GERD remains controversial in children and pediatric guidelines do not currently recommend empirical GERD treatment trials for pediatric chronic cough. Gastroesophageal reflux is more frequent in patients with cystic fibrosis (CF) than general population. Although PPIs are regularly prescribed in approximately half of the patients with CF, there are no specific guidelines for treatment of reflux in CF and it was shown that chronic treatment with PPIs was correlated to possible increased risk of exacerbations. CONCLUSIONS: The pathogenesis of GER-related respiratory symptoms is multifactorial. The causal relationship between these two conditions may be difficult to prove also with the aid of supporting tests. Multichannel intraluminal impedance associated with pH-metry (pH/MII) detect all gastroesophageal reflux episodes accompanied with a bolus movement and classify GER episodes according to their content (liquid, gas and mixed), pH value and proximal extension. There are no consistent evidences confirming the validity of medical therapy in reflux with respiratory symptoms.


Asunto(s)
Reflujo Gastroesofágico/epidemiología , Enfermedades Respiratorias/epidemiología , Niño , Monitorización del pH Esofágico , Reflujo Gastroesofágico/complicaciones , Reflujo Gastroesofágico/tratamiento farmacológico , Antagonistas de los Receptores H2 de la Histamina/administración & dosificación , Humanos , Inhibidores de la Bomba de Protones/administración & dosificación , Enfermedades Respiratorias/complicaciones , Enfermedades Respiratorias/fisiopatología
18.
Minerva Pediatr ; 71(6): 524-532, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31352766

RESUMEN

INTRODUCTION: Nitric oxide (NO) is a gas synthesized by the inducible NO synthase enzyme in airway cells and it is thought to make important functions in the airway inflammation of several respiratory diseases. EVIDENCE ACQUISITION: This current study is a review of the literature from 1990 to present about NO and its use in clinical practice. The databases used were PubMed, Scopus, and Cochrane Library. EVIDENCE SYNTHESIS: At the respiratory level there are three different measurements sites of NO: nNO (nasal nitric oxide), FeNO (exhaled fraction of nitric oxide), CaNO (alveolar nitric oxide). Each of them is produced at different levels of the respiratory tract and is involved in various diseases. nNO finds its use, principally, in the allergic rhinitis in fact it can be used as a measure of therapeutic efficacy, but not for the evaluation of the severity; also in primary ciliary dyskinesia (PCD), where high levels exclude the disease, and in chronic rhinosinusitis, but it is not currently used as a diagnostic or prognostic marker. FeNO has a greatest use in bronchial asthma, particularly, it is considered a non-invasive biomarker to identify and to monitor airway inflammation but currently, there is not a consensus on the use of the FeNO in the management of asthma treatment. Finally, CaNO is the least used in clinical practice, because lack of standardization of measurement techniques. CONCLUSIONS: Nitric oxide is a sensitive indicator of the presence of airway inflammation and ciliary dysfunction, although some studies have shown varying or conflicting results.


Asunto(s)
Inflamación/diagnóstico , Óxido Nítrico/metabolismo , Enfermedades Respiratorias/diagnóstico , Biomarcadores/metabolismo , Niño , Trastornos de la Motilidad Ciliar/diagnóstico , Trastornos de la Motilidad Ciliar/fisiopatología , Espiración/fisiología , Humanos , Inflamación/fisiopatología , Alveolos Pulmonares/metabolismo , Enfermedades Respiratorias/fisiopatología
19.
Adv Exp Med Biol ; 1067: 387-403, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29260415

RESUMEN

Optimal management of heart failure requires accurate risk assessment. Many prognostic risk models have been proposed for patient with chronic and acute heart failure. Methodological critical issues are the data source, the outcome of interest, the choice of variables entering the model, the validation of the model in external population. Up to now, the proposed risk models can be a useful tool to help physician in the clinical decision-making. The availability of big data and of new methods of analysis may lead to developing new models in the future.


Asunto(s)
Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/epidemiología , Humanos , Modelos Estadísticos , Análisis Multivariante , Pronóstico , Reproducibilidad de los Resultados
20.
Adv Exp Med Biol ; 1067: 239-253, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29235066

RESUMEN

Among comorbidity in chronic heart failure (CHF), dysthyroidism represents a relevant problem especially in the ageing CHF patients worldwide. Thyroid greatly affects many cardiovascular activities and its dysfunction may worsen a CHF condition. In particular, hypothyroidism has a relative high prevalence in patients with heart failure and it plays a key role in influencing CHF onset, progression and prognosis. Hyperthyroidism, is less frequent in this clinical context but it necessitates of immediate treatment because of its negative effects on cardiovascular balance. Also, it must be considered that dysthyroism may also be iatrogenic and the main responsible drug is Amiodarone.Based on the best available evidence and our cumulative clinical experience, this manuscript analyzes the prevalence, the pathophysiology and the prognostic impact of thyroid disorders in chronic heart failure.


Asunto(s)
Insuficiencia Cardíaca/complicaciones , Hipertiroidismo/fisiopatología , Hipertiroidismo/terapia , Hipotiroidismo/fisiopatología , Hipotiroidismo/terapia , Amiodarona/farmacología , Enfermedad Crónica , Humanos , Hipertiroidismo/inducido químicamente , Hipertiroidismo/complicaciones , Hipotiroidismo/inducido químicamente , Hipotiroidismo/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA